@article {MAISANO2871, author = {ROBERTO MAISANO and NICOLA CARISTI and MARZIA MARE and MARIO RAFFAELE and MONICA IORFIDA and ANTONINO MAFODDA and MARIA ZAVETTIERI and MARIO NARDI}, title = {Mitomycin C plus Capecitabine (MiXe) in Anthracycline- and Taxane-pretreated Metastatic Breast Cancer. A Multicenter Phase II Study}, volume = {27}, number = {4C}, pages = {2871--2875}, year = {2007}, publisher = {International Institute of Anticancer Research}, abstract = {Background: Capecitabine is considered the treatment of choice for anthracycline- and taxane-pretreated metastatic breast cancer. Mitomycin C seems to improve the activity of capecitabine by up-regulation of thymidine phosphorylase. Patients and Methods: Fifty-five women with metastatic breast cancer previously treated with anthracycline-taxane were treated with mitomycin C 10 mg/m2 on day 1 every six weeks and capecitabine 1000 mg/m2 on days 2-15 every three weeks. Results: An overall response rate of 38\% was found, consisting of 3 (5\%) complete responses (CR) and 18 (33\%) partial responses (PR); 8 patients (14\%) had a stable disease (SD) for more than 4 months. The combination was well-tolerated, with the main toxicities being neutropenia, diarrhea and fatigue; other toxicities were of mild to moderate intensity without impairment in the quality of life of the patients. Conclusion: Capecitabine is confirmed as the drug of choice in the treatment of anthracycline- and taxane-pretreated metastatic breast cancer and its combination with mitomycin appears to improve its efficacy.}, issn = {0250-7005}, URL = {https://ar.iiarjournals.org/content/27/4C/2871}, eprint = {https://ar.iiarjournals.org/content/27/4C/2871.full.pdf}, journal = {Anticancer Research} }